珠峰登山者心律失常风险的前瞻性队列研究
这项前瞻性队列研究在尼泊尔珠峰(8849米)纳入41名健康男性,基线与登山期间进行动态心律记录。13人(38.2%)发生主要终点事件,以缓慢性心律失常为主,多数事件发生在未使用 supplemental oxygen 的低海拔阶段,无人报告头晕或晕厥。
要点
- 健康登山者中超过1/3发生心律失常,以缓慢性心律失常为主。
- 多数心律失常事件发生在未使用 supplemental oxygen 的低海拔阶段。
- 无人报告头晕或晕厥,事件临床意义待进一步研究。
核心结论
- 在珠峰登山过程中,超过1/3的健康个体发生心律失常,证实高海拔暴露与心律失常发生相关。
研究设计与样本
- 前瞻性队列研究,在尼泊尔珠峰(8849米)纳入41名健康个体,2023年1月25日至5月9日招募,基线及登山期间行动态心律记录。
主要发现
- 5名参与者的9次心律失常(20%)发生在使用 supplemental oxygen 时,11名参与者的36次事件(80%)发生在未使用 supplemental oxygen 的低海拔阶段。
- 心律失常个体比例随海拔升高保持稳定,每24小时事件率在5300米为0.16、7300米为0.37,之后在使用 supplemental oxygen 的更高海拔下降。
- 无参与者报告头晕或晕厥。
关键数值与推荐
- 主要终点为室上性心动过速(>30秒)、室性心动过速(>3跳)及缓慢性心律失常(窦房传导阻滞、二度或三度房室传导阻滞)的复合终点。
临床怎么用
- 对于高海拔登山者,即使健康且基线心脏评估正常,仍需警惕心律失常风险,尤其在中低海拔未吸氧阶段。
局限性
- 样本量小(41人),全部为男性,平均年龄33.6(8.9)岁,结论外推受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Arterial hypoxemia, electrolyte imbalances, and periodic breathing increase the vulnerability to cardiac arrhythmia at altitude. OBJECTIVE: To explore the incidence of tachyarrhythmias and bradyarrhythmias in healthy individuals at high altitudes. DESIGN, SETTING, AND PARTICIPANTS: This prospective cohort study involved healthy individuals at altitude (8849 m) on Mount Everest, Nepal. Recruitment occurred from January 25 to May 9, 2023, and data analysis took place from June to July 2023. EXPOSURE: All study participants underwent 12-lead electrocardiogram, transthoracic echocardiography, and exercise stress testing before and ambulatory rhythm recording both before and during the expedition. MAIN OUTCOME: The incidence of a composite of supraventricular (>30 seconds) and ventricular (>3 beats) tachyarrhythmia and bradyarrhythmia (sinoatrial arrest, second- or third-degree atrioventricular block). RESULTS: Of the 41 individuals recruited, 100% were male, and the mean (SD) age was 33.6 (8.9) years. On baseline investigations, there were no signs of exertional ischemia, wall motion abnormality, or cardiac arrhythmia in any of the participants. Among 34 individuals reaching basecamp at 5300 m, 32 participants climbed to 7900 m or higher, and 14 reached the summit of Mount Everest. A total of 45 primary end point-relevant events were recorded in 13 individuals (38.2%). Forty-three bradyarrhythmic events were documented in 13 individuals (38.2%) and 2 ventricular tachycardias in 2 individuals (5.9%). Nine arrhythmias (20%) in 5 participants occurred when climbers were using supplemental bottled oxygen, whereas 36 events (80%) in 11 participants occurred at lower altitudes when no supplemental bottled oxygen was used. The proportion of individuals with arrhythmia remained stable across levels of increasing altitude, while event rates per 24 hours numerically increased between 5300 m (0.16 per 24 hours) and 7300 m (0.37 per 24 hours) before decreasing again at higher altitudes, where supplemental oxygen was used. None of the study participants reported dizziness or syncope. CONCLUSION AND RELEVANCE: In this study, more than 1 in 3 healthy individuals experienced cardiac arrhythmia during the climb of Mount Everest, thereby confirming the association between exposure to high altitude and incidence of cardiac arrhythmia. Future studies should explore the potential implications of these rhythm disturbances.
引用
- Sherpa K, Sherpa PP, Sherpa T, et al. Risk of Cardiac Arrhythmias Among Climbers on Mount Everest. JAMA Cardiol. 2024. PMID: 38568602. doi:10.1001/jamacardio.2024.0364
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。